Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: Induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity

@article{Scheid1994ImmuneFO,
  title={Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: Induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity},
  author={Christof Scheid and Rebekah L Young and Ray McDermott and Linda Fitzsimmons and J. H.. Thatcher Scarffe and Peter L. Stern},
  journal={Cancer Immunology, Immunotherapy},
  year={1994},
  volume={38},
  pages={119-126}
}
Interleukin-6 (IL-6) is a cytokine that acts on a variety of cell types, including myeloid progenitor cells and B and T lymphocytes. It has been found to activate cytotoxic T cells and natural killer (NK) cells and to induce T-cell-mediated antitumour effects in animal models. In a phase I clinical trial of recombinant human IL-6, 20 patients with advanced cancer were entered to receive daily subcutaneous injections of IL-6 over 7 days followed by a 2-week observation period and another 4 weeks… CONTINUE READING

13 Figures & Tables

Connections & Topics

Mentioned Connections BETA
At all dose levels IL-6 administration led to a marked increase in serum levels of C - reactive protein and a moderate rise in complement factor C3 .
At all dose levels IL-6 administration led to a marked increase in serum levels of C - reactive protein and a moderate rise in complement factor C3 .
All Topics